In vivo antidiabetic actions of naglivan, an organic vanadyl compound in streptozotocin-induced diabetes
- 31 May 1993
- journal article
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 20 (2) , 111-121
- https://doi.org/10.1016/0168-8227(93)90004-o
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Improvement of Glucose Homeostasis by Oral Vanadyl or Vanadate Treatment in Diabetic Rats is Accompanied by Negative Side EffectsBasic & Clinical Pharmacology & Toxicology, 1991
- Oral vanadium administration to streptozotocin-diabetic rats has marked negative side-effects which are independent of the form of vanadium usedToxicology, 1991
- Toxicological Aspects of Vanadyl Sulphate on Diabetic Rats: Effects on Vanadium Levels and Pancreatic B‐Cell MorphologyBasic & Clinical Pharmacology & Toxicology, 1990
- Sustained prevention of myocardial and metabolic abnormalities in diabetic rats following withdrawal from oral vanadyl treatmentMetabolism, 1989
- Correction of chronic hyperglycemia with vanadate, but not with phlorizin, normalizes in vivo glycogen repletion and in vitro glycogen synthase activity in diabetic skeletal muscle.Journal of Clinical Investigation, 1989
- Effect of Vanadate on Elevated Blood Glucose and Depressed Cardiac Performance of Diabetic RatsScience, 1985
- Acute toxicity of vanadium compounds in rats and miceToxicology Letters, 1984
- Insulin therapy in obese, non-insulin-dependent diabetes induces improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawalDiabetes, 1984
- Intestinal absorption and secretion of radioactive vanadium (48VO−3) in rats and effect of Al(OH)3Journal of Toxicology and Environmental Health, 1982
- Vanadium in foods and in human body fluids and tissuesScience of The Total Environment, 1978